Iceland· IS-EU/1/09/545/011-015
Onglyza
A saxagliptin product containing saxagliptinum inn hýdróklóríð, registered in Iceland by AstraZeneca AB. The same ATC class is registered in 16 of our 19 countries.
Checked against Icelandic Medicines Agency (Iceland) on
Informational only — not a medical device.
Where it is registered
Saxagliptin is registered in 16 of 19 countries.
Countries holding a registration under ATC A10BH03 (saxagliptin), each read from that country’s own register.
- This record: Iceland, from Icelandic Medicines Agency (Iceland)
- 10 of them publish a price we can compare per daily dose
Saxagliptin · ATC A10BH03
16 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Italyprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of saxagliptin costs, country by country.
Normalised to the WHO defined daily dose (5 mg), the median price runs from $0.31 in France to $3.59 in Italy — a ×12 gap.
- 3 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Saxagliptin · price per daily dose (5 mg)
USD · FX 28 Sept 2026
- IT Italy$3.59
- CH Switzerland$3.41
- FR France$0.31
The record
At a glance
Icelandic Medicines Agency (Iceland)- Active substance
- Saxagliptinum INN hýdróklóríð
- Manufacturer
- AstraZeneca AB
- Country
- Iceland (IS)
- ATC code
- A10BH03
- ATC class
- Saxagliptin
- Defined daily dose
- 5 mg, O
- Reimbursed
- Not published by this register
- Source register
- Icelandic Medicines Agency (Iceland)
- Last checked
- September 29, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
449 interactions on record for saxagliptin.
Graded by severity as the source publishes them — 3 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Saxagliptin · interactions on record
449 records
- 3 severe
- 404 moderate
- 42 minor
Most severe, free to view
- ClotrimazoleA01AB18moderate
- CimetidineA02BA01moderate
- SucralfateA02BX02moderate
- ThiethylperazinA04AB03moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Saxagliptin in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaONGLYZAAstraZeneca AB, Södertälje
- United StatesSaxagliptinAurobindo Pharma Limited
- BelgiumOnglyza 2.5 mgAstraZeneca
- NetherlandsOnglyza 2,5 mg, filmomhulde tablettenAstraZeneca AB
- IrelandOnglyza 2.5 mg film-coated tabletsAstraZeneca AB
- SpainONGLYZA 2,5 MG COMPRIMIDOS RECUBIERTOS CON PELICULAAstrazeneca Ab
- PolandOnglyzaAstraZeneca AB
- SwedenOnglyza 2,5 mg Filmdragerad tablettAstraZeneca AB
Authorised across Europe · EMA
The same active substance is authorised in 8 EEA countries. Names it is sold under:
- France · Saxagliptine Arrow, Saxagliptine Biogaran
- United Kingdom (Northern Ireland) · Saxagliptin Sandoz, Saxagliptin Zydus Pharmaceuticals Uk
- Hungary · Saxagliptin Pharos
- Liechtenstein · Onglyza
- Malta · Saxagliptin Pharos
- Netherlands · Saxagliptine Sandoz
- Norway · Onglyza
- Portugal · Saxagliptina Generis, Saxagliptina Generis Phar
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/64baa061-9cba-4af2-a95c-117847dfe326 GET /v1/drugs/64baa061-9cba-4af2-a95c-117847dfe326?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Filmuhúðuð tafla",
"source": "lyfjastofnun",
"atc_raw": "A10BH03",
"marketed": false,
"strength": "2,5 mg",
"ma_number": "EU/1/09/545/011-015",
"substance": "Saxagliptinum INN hýdróklóríð",
"other_info": null,
"legal_status": "(R) Lyfseðilsskylt",
"ma_issued_serial": "40647"
}See everything about saxagliptin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.